Immunity vs Cancer: Predicting who will gain from costly therapy
Cancer Immunity Biomarker

Immunity vs Cancer: Predicting who will gain from costly therapy

Dr. Talia Henkle
Dr. Talia Henkle

In 10 seconds? We continue our chat about cancer immune checkpoint therapies–which help our immune system attack cancer. One area showing progress is the quest for discrete biological features (AKA biomarkers) that indicate positive treatment outcomes in patients.

What’s the story? In our last Immunity vs Cancer digest, we learned that 'immune checkpoint inhibitors–or ICI'  have been game-changers in treating some advanced-stage cancers–with response rates (AKA improvement in cancer burden) that range from 10% to 60%.


Get unlimited access to our 3-min Digests and other premium features!

Choose your plan.

Sparrow Insiders

$0 (Limited Offer)
  • Receive our daily Digest in your inbox
  • Created & reviewed by real scientists
  • Preview 380+ Digests in our library
  • Upgrade for unlimited learning
  • Unsubscribe anytime
  • Subject to availability
Join our first 25k subscribers for free! Signup Progress Bar Subscribe now for free

Sparrow Unlimited

$19 / month
  • Talk with our scientists and ask them anything
  • Access 380+ summaries anywhere, anytime
  • Listen to our premium podcast
  • Weekly newsletter of the top 5 scientific findings
  • Daily updates with new content
  • Support independent science publishing
  • No advertisement
  • Cancel anytime
Learn more Subscribe now

Sparrow Unlimited

$99 / year
  • One easy payment - save 56%
  • Talk with our scientists and ask them anything
  • Access 380+ summaries anywhere, anytime
  • Listen to our premium podcast
  • Weekly newsletter of the top 5 scientific findings
  • Daily updates with new content
  • Support independent science publishing
  • No advertisement
  • Cancel anytime
Learn more Subscribe now